目前尚缺乏对低级别胶质瘤（LGG）诊断成年人生活质量（QOL）进行大规模研究的资料。本研究采用医学成果研究36项短表健康调查（Medical Outcomes Study 36-Item Short Form health survey）评估了320名LGG受试者（世界卫生组织2/3级）的生活质量。同时还收集了症状数据。将治疗组的QOL结果进行了分析，并与流行病学研究中的髓母细胞瘤对照研究（髓母细胞瘤联合组织）进行了对比。该研究纳入了在康涅狄格州、马萨诸塞州、加利福尼亚州、德克萨斯州和北卡罗来纳州在2006年5月1日到2013年3月14日期间诊断的1722例髓母细胞瘤病例，并按照年龄、性别和地理位置进行了频率匹配，与1622例对照组进行了对比。LGG样本的平均年龄在访谈时为45岁，男性占53.1%。将近55%的患者接受了放疗和化疗（主要是替莫唑胺）；32.4%的患者没有接受任何治疗。三分之二的LGG患者报告说在言语、记忆或思维方面存在困难，超过三分之一的患者报告出现人格变化或驾驶困难。在控制年龄和其它合并症的影响后，LGG患者的身体、情绪和心理健康状况报告均低于髓母细胞瘤和一般健康人群的报告水平。尽管年龄相对较轻，LGG患者的生活质量明显降低，与非恶性脑肿瘤患者和对照人群相比，这突显了对这一生活黄金期被诊断出患有该病的患者更好地认识和管理这些症状的需求。©2023 The Authors. 由美国癌症协会代表Wiley Periodicals LLC出版的《癌症》杂志刊登。

Few large studies have investigated quality of life (QOL) for adults diagnosed with lower grade glioma (LGG).QOL was assessed for 320 adults with LGG (World Health Organization grade 2/3) enrolled in the International Low Grade Glioma Registry by using the Medical Outcomes Study 36-Item Short Form health survey. Data on symptoms were also collected. QOL outcomes were examined by treatment group and also compared to those from a population-based case-control study of meningioma (the Meningioma Consortium), in which 1722 meningioma cases diagnosed among residents of Connecticut, Massachusetts, California, Texas, and North Carolina from May 1, 2006 through March 14, 2013 were enrolled and frequency matched to 1622 controls by age, sex, and geography.The LGG sample average age is 45 years at the time of interview and 53.1% male. Almost 55% of patients had received radiation and chemotherapy (primarily temozolomide); 32.4% had received neither treatment. Two-thirds of participants with LGG report difficulty with speaking, memory, or thinking, and over one of three reports personality change or difficulty driving. After controlling for age and other comorbidities, individuals with LGG report levels of physical, emotional, and mental health functioning below those reported in a meningioma as well as a general healthy population.Despite being relatively young, persons with LGG report significantly reduced QOL compared to persons with nonmalignant brain tumors and to a control population, which highlights the need to better acknowledge and manage these symptoms for this group of patients diagnosed in the prime of life.© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.